Worried about the Vaccine? Federal Agencies Lift Recommended Pause on Janssen COVID-19 Vaccine in the US
Vaccine fact sheets for healthcare providers, recipients, and caregivers were updated to reflect the low risk of blood clots.
It has been over a year since the novel coronavirus was officially declared a pandemic. However, there is a light at the end of the tunnel with the introduction of several vaccines into the global market. Many countries still face challenges regarding procurement and distribution, including several that have yet to administer a single dose. As of February 2021, at least 130 countries fit these criteria, according to UNICEF.
There have and remain logistical concerns regarding vaccination. The FDA and CDC’s recommended pause in Jonson & Johnson COVID-19 vaccine use is one of several hurdles that have cropped up. Six reported cases of a rare side effect of developing severe blood clots following vaccine administration led to the temporary pause. However, the pause has recently been lifted, and the Janssen COVID-19 vaccine will continue to be distributed in the United States. The vaccine was determined safe, and the vaccine fact sheets for healthcare providers, recipients, and caregivers were updated to reflect the low risk of blood clots.
About James Goydos, M.D.
James Goydos is an expert in melanoma research and specialist in surgical oncology with an M.D. from Rutgers University. With over 20 years of experience as a Professor, Surgeon, and Clinical Trial Lead, he is a leading expert in his field.
Subscribe to James Goydos’ newsletter. Follow me on Good Men Project, Loop, Medium, Instagram, Facebook, YouTube, Medika Life, Doximity, Github, Kaggle, Vocal, LinkedIn, Pinterest, and Twitter!
